Which option best summarizes the definitions used in the FDA framework for new drugs?

• A. Clean definition
• B. Different formulation
• C. Different indication
• D. All of the above

Answer: (D)

In regulatory terms, what counts as a new drug is defined by multiple ways the product can be meaningfully different from existing products. A clear, unambiguous terminology is essential so regulators apply the rules consistently. A change in formulation can alter how the drug is released, absorbed, or tolerated, which can create a product with a different safety or efficacy profile and often requires fresh regulatory review. A new therapeutic indication changes the labeling, the risk–benefit assessment, and the amount and type of data needed to support approval. And a new chemical identity or entity is the most traditional line separating a new drug from an existing one. Because the FDA framework uses all of these dimensions to determine whether something is a new drug or a line extension, the best answer is that all of these aspects are encompassed by the definitions used in that framework.